Please assess the completion status of the following clinical trial:

Trial Title: Sodium Nitroprusside in Early Course Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Having a DSM-V diagnosis of Schizophrenia or schizoaffective disorder with \<5 years from the onset of psychosis~* Having up to 2 years of lifetime exposure to antipsychotics~* Having total score of \>65 on the Positive and Negative Syndrome Scale (PANSS) with a score of \>4 on 1 or more PANSS items (delusions, conceptual disorganization, hallucinatory behavior, suspiciousness, or unusual thought content)~* Having English proficiency~* Being competent and willing to give informed consent~Exclusion Criteria:~* Having substance dependence or abuse within the past 6 months~* Having history of retinal disease; myopia \>4.0 diopters; symptomatic orthostatic hypotension~* Any change of psychotropic medications within the previous 4 weeks~* Currently taking clozapine~* Having prior history of intolerance to Sodium Nitroprusside~* Having treatment with medications that may interfere with the metabolism or excretion or effects of Sodium Nitroprusside~* Being pregnancy/breast feeding~* Having unstable major medical (renal, hepatic, or cardiac) or neurologic illness~* Having significant inflammatory or immune conditions~* Having treatment with anti-inflammatory drugs, hormones or immunosuppressant agents in the 6 months before study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Nitroprusside Arm (Type: EXPERIMENTAL): Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
- Placebo Arm (Type: PLACEBO_COMPARATOR): 5% Dextrose (0.5 μg/kg/min) for 4 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).